Exact Sciences Corporation
EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Testā¦ read more
Healthcare
Diagnostics & Research
24 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$45.09
Price-1.12%
-$0.51
1Y
Price
Market Cap
$8.536b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-13.6%
EBITDA Margin-14.3%
Net Profit Margin+0.0%
Free Cash Flow MarginRevenue
$2.940b
+2.5%
1y CAGR+10.9%
3y CAGR+12.7%
5y CAGREarnings
-$1.005b
+0.9%
1y CAGR-111.9%
3y CAGR-85.1%
5y CAGREPS
-$5.43
+1.4%
1y CAGR-108.4%
3y CAGR-81.7%
5y CAGRBook Value
$2.469b
$5.797b
Assets$3.328b
Liabilities$2.537b
DebtDebt to Assets
43.8%
-3x
Debt to EBITDAFree Cash Flow
$169.618m
+160.4%
1y CAGR+133.7%
3y CAGR+79.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company